HHS Pick, Former Eli Lilly Exec, Grilled over Zyprexa Scandal
Researchers Concerned About Over-Prescription of Risperdal
The most recent study published on the use of antipsychotics, such as Risperdal, Zyprexa and Seroquel, in children with ADHD has researchers concerned that there may be an over-prescription problem. The study published January 19, 2017 in The Canadian Journal of Psychiatry shows the same dramatic increase in use of antipsychotics prescribed off-label in children with ADHD, ages 1 […]
#6 & #11 PA SETTLEMENTS 2014
American Lawyer Media’s Top Pennsylvania Verdicts and Settlements for 2014 reveals Sheller, P.C. in a familiar spot again in 2014. The firm has been at or near the top of the list for five of the last six years. This year the firm pulled both the #6 and #11 Top Settlements spots based on its […]
$58.9 MILLION SETTLEMENT
The Sheller whistleblower team announced a $58.9 milllion settlement with Shire Pharmaceuticals over off-label marketing of ADHD drugs Adderall and Vyvanse in September, 2014. Court documents detailing the civil allegations and settlement were signed by Shire and unsealed by the Office of the United States Attorney for the Eastern District of Pennsylvania. A Shire executive, […]
$7.3M Astellas Pharma Off-Label Marketing and FCA Settlement
Digital Journal 2014-04-16 The whistleblower attorney team of Sheller P.C. announced today that Astellas Pharma U.S., Inc. has agreed to pay $7.3 million to resolve allegations by the Sheller whistleblower client that Astellas violated the False Claims Act by submitting fraudulent claims to government healthcare programs while marketing off-label the antifungal drug Mycamine for use in children. Court […]
Sheller in Bloomberg Business on Whistleblowers and J&J $2.2B Settlement
Bloomberg Business Week 2013-12-09 Judy Doetterl was a sales representative for Johnson & Johnson (JNJ) in 2004 when federal agents placed a hidden recording device on her and sent her to tape marketing presentations at a national company sales meeting. U.S. prosecutors wanted to prove claims by Doetterl and others that J&J boosted sales by urging doctors to prescribe […]
Sheller in Philadelphia Inquirer on $2.2B Risperdal Settlement
Philadelphia Inquirer 2013-11-05 Sheller, P.C.’s representation of whistleblowers totals over $6 billion, with three of the top five pharmaceutical settlements in history: 2009: Pfizer $2.3 billion (Geodon) 2009: Eli Lilly & Co. $1.4 billion (Zyprexa) 2013: Johnson & Johnson $2.2 billion (Risperdal, Invega) and in 2010 : Astra Zeneca $520 million (Seroquel) WASHINGTON – Health-care […]
